Celcuity

CELCNASDAQ

CELsignia: a functional signaling pathway analysis platform that identifies abnormal signaling in patient tumor cells to guide targeted therapy selection and enable more precise clinical trials.

Drafted with AI assistance from public sources and not individually reviewed by an editor; last updated 2026-10-02. Published by Blane Jackson, DDS, MBA. Educational analysis only. Read the editorial policy and disclosures.

Filing figures as of June 30, 2026 · text updated 2026-10-02 · where each field comes from

Oncology

Key figures from SEC filings

CELC filings on EDGAR →

Cash & investments

$754M

at June 30, 2026 (10-Q)

Quarterly operating burn

$55.2M

average per quarter, Jan–Jun 2026

Cash runway

~41 months

$754M ÷ $55.2M per quarter

Shares outstanding

48.9M

cover page of the latest filing

Read from CELC's XBRL financial data; latest filing August 13, 2026; fetched 2026-09-28. Runway assumes the reported burn continues unchanged; burn usually rises as programs advance, so treat it as an upper bound. Revenue stage: Early revenue.

Upcoming catalysts

No upcoming catalyst for Celcuity has been confirmed against a primary source. Rather than estimate one, this section is left empty — check the company's investor relations page and ClinicalTrials.gov directly.

Pipeline

DrugIndicationPhaseExpected data
REVTORPYK (gedatolisib)HR+/HER2-, PIK3CA wild-type advanced breast cancer after endocrine therapyApprovedNot disclosed▼
GedatolisibHR+/HER2- advanced breast cancer (first-line)Phase 32027▼
GedatolisibMetastatic castration-resistant prostate cancer (mCRPC)Phase 12026▼
GedatolisibEndometrial cancerPhase 2Not disclosed▼
GedatolisibAdvanced triple-negative or BRCA1/2 positive, HER2-negative breast cancerPhase 1Not disclosed▼
Neratinib + CapmatinibMetastatic breast cancer with abnormal HER-family and c-Met activityPhase 1Terminated▼
NeratinibTriple-negative breast cancer with abnormal HER2 signalingPhase 2Unknown▼

Analysis

We have not yet written an analysis of Celcuity that is specific and current enough to publish. Earlier text here was removed rather than left up: on most profiles it was a template shared with other companies, and where a correction is listed above, it was written before the facts changed. The filing figures, pipeline and sourced catalysts on this page are current; the written thesis will be added from them.
Trade CELC commission-free on Webullvia Webull · Affiliate

Comparable companies

PBYIRXRXNTLA

Sponsored

Get premium CELC analysis on Seeking Alpha

Affiliate link — we may earn a commission at no cost to you

Disclaimer: This page is for informational and educational purposes only and does not constitute financial advice or a recommendation to buy or sell securities. Clinical trial analysis reflects publicly available data and AI-generated interpretations. Biotech investing carries significant risk including potential total loss of investment. Always verify critical claims through primary sources and consult a qualified financial advisor. Some links on this page are affiliate links. Review our editorial policy and disclosures.

Cash against the next catalyst

Funded through this catalyst

Cash reaches roughly Q4 2029 on the disclosed figures, about 11 quarters past this Q1 2027 catalyst — the readout is funded without a raise.

  • Derived from $754M ÷ $55M per quarter, both self-reported.
  • Burn usually rises as a programme moves through late-stage trials, so this is an upper bound.

This is the arithmetic between two dates, not a forecast. Companies raise early from strength, delay programmes, partner, or borrow.

Sponsor's late-stage trial record

Celcuity has 3 Phase 2 or 3 studies on ClinicalTrials.gov: 3 ongoing.

0

Completed

0

Stopped early

3

Ongoing

Counts cover interventional Phase 2 and Phase 3 studies registered under this sponsor name, retrieved 2026-09-28 from ClinicalTrials.gov API v2. Trials stop for many reasons — futility, safety, enrollment, funding, or a decision to back a different programme — and the registry often does not say which. This is the sponsor's record, not a prediction about any specific readout.